| CERTAIN-CUSTOMERS |
CERTAIN-CUSTOMERS |
90%
|
The Company will likely incur additional costs related to the recall in 2026 which are currently estimated to be approximately $75,000 in new capsule inventory and $25,000 to $75,000 a week in lost r… |
| ALPHA-NUCLIDE-INC |
ALPHA-NUCLIDE-INC |
85%
|
lted in significant lost sales for this business segment. Our supply of cobalt-57 was restored in July 2024, and we added additional suppliers in 2024. In 2025, we did not experience any shortages of… |
| RADVENT-LLC |
RADVENT-LLC |
80%
|
These acquired assets from AMICI are currently under development and are expected to be released in the second half of 2025 to be sold through our RadVent subsidiary as part of our Medical Devices segment |
| PHANTECH-LLC |
PHANTECH-LLC |
70%
|
On August 6, 2024, the Company entered into a joint venture agreement with Phantech LLC to form PhanQual |
| AMERICAN-FUEL-RESOURCES-LLC |
AMERICAN-FUEL-RESOURCES-LLC |
62%
|
Reference Products 2,145,825 16 % 1,709,369 12 % Medical Devices Products 198,490 2 % 8,790 0 % Fluorine Products — — % — — % Total Segments $ 5,367,680 41 % $ 5,251,207 38 % Gross Profit $ 7,702,656… |
| INTERNATIONAL-ISOTOPES-IDAHO-INC |
INTERNATIONAL-ISOTOPES-IDAHO-INC |
62%
|
Item 1. BUSINESS General Business and Products Description Radnostix Inc. (the “Company”, “we”, “us” and “our”) manufactures a wide range of radioisotope-focused products used in variety of medical a… |
| INTERNATIONAL-ISOTOPES-INC |
INTERNATIONAL-ISOTOPES-INC |
62%
|
Item 1. BUSINESS General Business and Products Description Radnostix Inc. (the “Company”, “we”, “us” and “our”) manufactures a wide range of radioisotope-focused products used in variety of medical a… |
| KENNERMAN-ASSOCIATES-INC |
KENNERMAN-ASSOCIATES-INC |
62%
|
April 30, 2026, reporting beneficial ownership as of December 31, 2025, for which Kennerman Associates, Inc. d/b/a Kershner Grosso & Co. has shared dispositive power and includes shares of various in… |
| NORTH-AMERICAN-SPECIALTY-INSURANCE-COMPANY |
NORTH-AMERICAN-SPECIALTY-INSURANCE-COMPANY |
62%
|
NOTE 11 – COMMITMENTS AND CONTINGENCIES Dependence on Third Parties Sales during 2025 to the Company’s top three customers was approximately 31 % of its total gross revenue. The Company is making eff… |
| OVERVIEW-RADNOSTIX-INC |
OVERVIEW-RADNOSTIX-INC |
62%
|
Item 1A. of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described herein or implied by such forward-looking statemen… |
| RADQUAL-LLC |
RADQUAL-LLC |
62%
|
IX INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED December 31, 2025 AND 2024 NOTE 1 – DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES Description of … |